|
 The 8th U.S. Circuit Court of Appeals in St. Paul, Minnesota said a
lower court judge erred in finding that the plaintiff shareholders
sued too late, by waiting more than two years after learning
information that could suggest an intent to defraud.
Medtronic did not respond to requests for comment.
The plaintiffs include the West Virginia Pipe Trades Health and
Welfare Fund, the Employees' Retirement System of the State of
Hawaii and Germany's Union Asset Management Holding AG.
Medtronic developed Infuse as an alternative to bone grafts, and the
U.S. Food and Drug Administration approved it for use in some lower
back spinal surgeries in 2002.
But off-label uses of Infuse eventually comprised 85 percent of
sales. The FDA in 2008 warned against such uses, following reports
of life-threatening complications.
Three years later, a June 28, 2011 article in The Spine Journal said
clinical studies by doctors with financial ties to Medtronic
understated Infuse's risks.
Then in October 2012, the U.S. Senate Finance Committee found that
Medtronic was "heavily involved" in shaping the content of such
studies.
Shareholders sued Medtronic on June 27, 2013, saying its activities
inflated the company's stock price, and caused them to lose hundreds
of millions of dollars as the truth came out.
In Wednesday's decision, Circuit Judge Raymond Gruender said it was
not until The Spine Journal article was published that reasonable
shareholders might have inferred that problems with Medtronic's
studies reflected an intent to defraud.
Gruender also said shareholders properly alleged that they relied on
Medtronic's alleged misconduct.
"A company cannot instruct individuals to take a certain action, pay
to induce them to do it, and then claim any causal connection is too
remote when they follow through," he wrote.
[to top of second column] |
"In this way," the judge continued, "Medtronic's alleged
manipulative conduct directly caused the biased clinical trial
results that the market relied upon."
Shawn Williams, a lawyer for the plaintiffs, said he was pleased
with the decision, which returns the case to the lower court for
further proceedings.
Medtronic is now based in Ireland, but has offices in Minneapolis.
In March 2012, the company agreed to pay $85 million to settle a
shareholder lawsuit claiming it concealed the extent of Infuse's
off-label use. (http://www.reuters.com/article/us-medtronic-settlement-idUSBRE82T1A920120330)
The case is West Virginia Pipe Trades Health & Welfare Fund et al v.
Medtronic Inc et al, 8th U.S. Circuit Court of Appeals, No. 15-3468.
(Reporting by Jonathan Stempel in New York; Editing by Marguerita
Choy)
[© 2016 Thomson Reuters. All rights
reserved.] Copyright 2016 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |
